PBSVOTCServices-Management Consulting ServicesFiscal year ends October 31
Pharma-Bio Serv, Inc.
Financials through Q3 FY2026, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 14, 2026
$0.48+0.08 (+20.00%)
Close on Oct 19, 2026
- Market cap
- $11.00M
- P/E (TTM)
- 48.0
- Dividend yield
- –
Pharma-Bio Serv, Inc. revenue by segment
By business segment
By product or service
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Puerto Rico Consulting [Member] | $4.64M | $5.69M | $8.04M | $12.14M | $14.68M | $18.21M | $16.80M | $14.44M | $10.94M | $14.58M | 51.5% | -18.5% |
| United States Consulting [Member] | $2.62M | $3.16M | $4.67M | $4.56M | $2.72M | $2.28M | $2.19M | $2.14M | $1.22M | $1.45M | 29.1% | -17.1% |
| Europe Consulting [Member] | $1.73M | $571.18K | $4.26M | $2.65M | $2.33M | $829.17K | $315.33K | $1.15M | $1.09M | $815.93K | 19.2% | +202.4% |
| Other Segment [Member] | $16.67K | $85.78K | $6.23K | $47.65K | $384.49K | $237.16K | – | – | – | – | 0.2% | -80.6% |
| Lab (microbiological and chemical testing) | – | – | – | – | – | – | – | – | $2.04M | $2.45M | – | – |
| Other Segments | – | – | – | – | – | – | $205.52K | $67.17K | $56.28K | $246.60K | – | – |
| Brazil Consulting | – | – | – | – | – | $237.16K | $205.52K | – | – | – | – | – |
From the segment and revenue-disaggregation notes of Pharma-Bio Serv's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.